Clinical and Economic Burden of Invasive Escherichia coli Disease Among Commercially Insured Adult Patients in the United States

Author(s)

El Khoury AC1, Hernandez-Pastor L2, Geurtsen J3, Kalu N4, Singh R5, Verma S5, Baugh B6
1Janssen Global Services, Raritan, NJ, USA, 2Janssen Pharmaceutica NV, Beerse, Belgium, 3Janssen Vaccines & Prevention BV, Leiden, Netherlands, 4Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 5STATinMED, LLC, Dallas, TX, USA, 6Janssen Research & Development, LLC, Raritan, NJ, USA

OBJECTIVES: Extraintestinal pathogenic Escherichia coli may cause invasive E. coli disease (IED). This study evaluated the clinical and economic burden of IED among commercially insured adults in the United States.

METHODS: Commercially insured adults (18-64 years) with diagnosis codes indicative of IED were identified in RWD Insights, an all-payer medical and pharmacy claims database, from 01/2018-12/2018. Index date was defined as date of first IED diagnosis. Patients were required to have ≥12 months continuous data capture pre/post-index date. Non-IED patients had no prior evidence of IED. Demographic and clinical characteristics were assessed during 12-month baseline. Preliminary propensity score matching (PSM) was conducted between IED and non-IED cohorts using selected demographic and clinical characteristics with further evaluation and validation of diagnosis categories used in PSM ongoing. Cox proportional hazards model was used to examine time to all-cause death. Generalized linear models were implemented to compare healthcare resource utilization (per patient per year) and costs (per patient per month).

RESULTS: A total of 7,588 IED and 525,736 non-IED patients were included. At baseline, IED patients, compared with non-IED, were older (52.4 vs 44.8 years, p<0.0001), included more females (68.5% vs 57.5%, p<0.0001), and had higher mean Charlson Comorbidity Index score (2.47 vs 0.22, p<0.0001). 85% (n=6,432) of IED patients were treated in inpatient setting, with 25% (n=1,584) receiving ICU care. Post-PSM, IED cohort (N=6,889) incurred significantly higher healthcare costs ($8,645 vs $1,054, p<0.0001) than matched controls, primarily due to inpatient costs ($7,472 vs $1,458, p<0.0001). In the IED cohort, risk of inpatient admission in follow-up was 4.08 times higher (CI: 3.96-4.20, p<0.0001); risk for death was 4.73 times higher (CI: 3.99, 5.62, p <0.001).

CONCLUSIONS: IED was found to be associated with substantial clinical and economic burden, when a cohort of IED cases was compared with matched controls, thus highlighting a critical need for preventative measures.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

EE238

Topic

Economic Evaluation

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×